Trials / Completed
CompletedNCT01941407
First Line Metastatic Breast Cancer Treatment (ESMERALDA)
A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- ARCAGY/ GINECO GROUP · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of eribulin is now well known in metastatic breast cancer. Furthermore, a phase III combine study ( chemo + bev)in metastatic first line shown a gain in PFS with no extra toxicities. It could be interesting to explore the combination of bev + eribulin in first line metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eribulin | Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2014-08-01
- Completion
- 2016-03-01
- First posted
- 2013-09-13
- Last updated
- 2016-03-17
Locations
40 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01941407. Inclusion in this directory is not an endorsement.